Moderna’s Coronavirus Vaccine 95% Effective In Clinical Trial
Moderna, Inc. — a major beneficiary of government funds under President Donald Trump’s ‘Operation Warp Speed’ — said on Monday that its potential coronavirus vaccine was found to be 94.5% effective in clinical trials.
We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study.
Read more: https://t.co/vYWEy8CKCv pic.twitter.com/YuLubU1tlx
— Moderna (@moderna_tx) November 16, 2020
“We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study,” the biotechnology firm said in announcing the promising results of its vaccine candidate in preventing the coronavirus.
The positive development came a week after pharmaceutical giant Pfizer, in partnership with German pharmaceutical company BioNTech also reported on November 9, a successful COVID-19 vaccine trial with over 90% efficacy.
President Trump lauded the news from Moderna.
“Another Vaccine just announced. This time by Moderna, 95% effective. For those great “historians”, please remember that these great discoveries, which will end the China Plague, all took place on my watch!” President Trump tweeted shortly after the news broke.
“Stock market getting very close to 30,000 on new vaccine news. 95% effective!” he added.
Operation Warp Speed
Moderna participated in the government’s ‘Operation Warp Speed,’ initiated by President Trump to fast-track the development of COVID-19 vaccines and therapeutics.
The federal government — through the Department of Health and Human Services (HHS) — granted the Massachusetts-based Moderna US$955 million to develop its vaccine. The first US$483 million was granted when Moderna entered the Phase 1 trial for its vaccine candidate in March, and another US$472 million was granted in July to support the Phase 3 of its clinical trial.
The government also agreed to a US$1.5 billion deal with Moderna in August “to buy, manufacture, and distribute” the first 100 million doses of the vaccine candidate once approved — with the option for more purchases.
Moderna worked with researchers at the National Institute of Allergy and Infectious Diseases to develop the vaccine, and also design the firm’s clinical trials.
President Trump and Dr. Moncef Slaoui, who leads Operation Warp Speed, already hinted at the good news from Moderna’s clinical trial last week.
“I would expect that shortly — probably next week — we may hear what I hope to be another very good information regarding an efficacious vaccine,” Dr. Slaoui said in a press briefing.
Unlike Pfizer’s potential COVID-19 vaccine which needs a special freezer with a temperature of -94 degrees Fahrenheit, Moderna’s vaccine-candidate can be stored in a standard refrigeration temperature of 25 degrees Fahrenheit making it more feasible for worldwide mass transport.
Share Your Thoughts
We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spam, instead of replying to it please hover over that comment, click the ∨ icon, and mark it as spam. Thank you for partnering with us to maintain fruitful conversation.